{"publication_id":"1c7cde7e-d3f8-4ef8-8e27-3138d9d41d0b","screening":{"identified":2,"screened":2,"excluded":0,"included":2,"included_or_retained":2,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"2 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted alpha memo, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["**Alpha (1 sentence):** The same drug class anchor (\"antidiabetes agent + exercise\") splits by compound — dapagliflozin lets adaptation signal travel, while metformin both impairs adaptation and independently protects muscle from damage — so a single \"protection\" tag cannot be treated as a benefit on the exercised-muscle endpoint.","**Selection basis:** Chosen because the pair holds the anchor constant (antidiabetes drug + endurance exercise) while the compound changes, isolating drug identity as the variable behind opposite-sign results on related but non-identical endpoints.","vehicle — to test whether metformin's damage-marker reduction coexists with attenuated adaptation in the same cohort, or whether the protection and attenuation signals are dissociable."]}